Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2024-02-09 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in voting rights percentages, acquisition/disposal of shares/instruments, and a breakdown of holdings by legal entities (The Goldman Sachs Group, Inc. and its subsidiaries). This structure perfectly matches the definition of a notification regarding changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a formal disclosure of share ownership changes, not the results of a vote (DVA).
2024-02-09 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and references Article 40, Section 1 of the WpHG (German Securities Trading Act). It details changes in share ownership ('Notification of Major Holdings') for specific individuals (Robert Atchinson, Phillip Gross) and reports the resulting percentage change in voting rights (from 5.01% to 0.00%). This directly corresponds to the definition of reporting changes in significant share ownership thresholds, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although the header mentions 'Voting Rights Announcements', MRQ is the specific regulatory filing type for tracking these ownership changes.
2024-02-08 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing the 'Notification of Major Holdings' as per German Securities Trading Act (WpHG). It reports changes in the percentage of voting rights held by Morgan Stanley in MorphoSys AG, crossing specific thresholds (Section 6 and 7). This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which aligns best with the Major Shareholding Notification (MRQ) category, although the header mentions 'Voting Rights Announcements'. Since 'MRQ' specifically covers changes in significant share ownership, it is the most precise fit among the provided options, as DVA is for voting results, not ongoing holding changes.
2024-02-07 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains a section labeled 'Notification of Major Holdings'. It details changes in the percentage of voting rights held by Morgan Stanley in MorphoSys AG, crossing specific thresholds (e.g., total position crossing 10.05%). This directly corresponds to the definition of a major shareholding notification, which in the provided list is categorized as 'Major Shareholding Notification' (MRQ). Although the header mentions 'Voting Rights Announcements', the content structure (reporting thresholds crossed by a specific entity) aligns best with MRQ, which covers changes in significant share ownership levels.
2024-02-06 English
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for 2.7 Billion Equity Value
M&A Activity Classification · 1% confidence The document is a press release dated February 5, 2024, announcing that MorphoSys AG has entered into a Business Combination Agreement to be acquired by Novartis for € 2.7 Billion. It details the terms of a voluntary public takeover offer, the sale of tafasitamab rights to Incyte, and mentions upcoming regulatory filings like the Tender Offer Statement on Schedule TO and Solicitation/Recommendation Statement on Schedule 14D-9 to be filed with the SEC. The core subject is a major corporate transaction involving a takeover/merger proposal. This aligns directly with the definition for M&A Activity (TAR). Although it mentions future SEC filings, the primary content is the announcement of the M&A deal itself, not a general regulatory filing (RNS) or a report publication announcement (RPA).
2024-02-05 English
Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
M&A Activity Classification · 1% confidence The document is explicitly labeled as an "Ad-hoc" announcement and discloses "inside information according to Article 17 MAR". The core content details a proposed acquisition of MorphoSys AG by Novartis via a voluntary public takeover offer, and a separate agreement to sell rights to Incyte. This describes a significant corporate transaction involving a merger/acquisition proposal and a disposal of assets. This falls directly under the definition of M&A Activity (TAR). Although it mentions filing documents like Schedule TO and Schedule 14D-9 with the SEC, the document itself is the initial announcement of the transaction, not the final proxy statement (DEF 14A/PSI) or the final report (10-K). Therefore, TAR is the most appropriate classification.
2024-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.